About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

Maybe their IP is worth 10p a share, nice liquidation proceeds on the way.............................watch out, there's another flying pig!!

Sorry for losers here all except potatohead.

Deserves what he gets and I hope he is mashed.

Bloody pump and dumper.

RNS Number : 7588B
EiRx Therapeutics PLC
20 August 2008



Eirx Therapeutics plc ('the Company')




Resignation of Director, Liquidation of subsidiary




Eirx Therapeutics plc announced today that it is applying to put its wholly owned Irish subsidiary Eirx Therapeutics Limited.('ETL') into liquidation. Michael McAteer of Foster McAteer, Chartered Accountants, Dublin has been asked to allow his name to go forward for appointment as liquidator of ETL.




Colin Telfer the CEO has been made redundant as part of the liquidation process, and has resigned as a director of the Company effective 19 August 2008. The board of EiRx would like to express its gratitude to Dr Telfer for all his efforts on behalf of the Company. John Pool, Nick Strong and Tom Cotter remain as directors.




The directors of Eirx Therapeutics plc are working to put together a plan designed to secure the future of the Company based around its other operating business, Auvation Limited. Further announcements will be made as appropriate.

A sad end by the looks of it.

"EIRX PLOTS RETURN WITH A 15M LISTING

The fundraising will allow EiRx to invest in up to nine companies

Monday March 28,2011
By Andrew Johnson

Comment Speech Bubble Have your say(0)

LIFE sciences specialist EiRx Therapeutics is plotting a return to Aim after being forced to de-list more than two years ago.

It is hoping to raise 15million in the move, which should go ahead in June and is expected to value the company at about 50million.

EiRx was compelled to leave Aim after the Bank of Scotland pulled promised funding in 2008 during the financial crisis.

Chairman John Pool says the plan is to create a specialist life sciences investment and management business aimed at mitigating the risks associated with early-stage companies in the sector.

The fundraising will allow EiRx to invest in up to nine companies in two main areas anti-infectives and cancer treatments.

Some are already generating revenues, one is close to signing an agreement with a big German medical devices group thought to be Bayer while others are seeking funding for clinical trials.

EiRx is currently seeking 920,000 in a pre-float fundraising to conduct due diligence and back the move onto Aim.

The money raised in the float will also allow EiRx to continue to invest in its businesses without having to constantly seek further funds.

In the future, the company hopes to expand into other areas, such as cardiovascular treatments.

The proposed chief executive is Kris Matykiewicz, formerly of AstraZeneca, while non-executives include Professor Andrew Porter, of the University of Aberdeen, and AstraZeneca director of safety science, Dr John Pears.

http://www.express.co.uk/posts/view/237200/EiRx-plots-return-with-a-15m-listing

Have you subscribed Driver? For old times sake I've put down all of 180. :o)

kim

No i sold all my ERX before it went tits up will be watching with interest.

amoeba bio companies have an exceptionally high mortality rate

I've been waiting to use them as a loss against capital gains. Looks like I might have to wait a bit longer Driver!

Very true Cynic!

Just cast me eye over the thread on the Dark side.. twichy bunch esp Mike111D , not sure how they will fair with things as they are ?? but still Interesting to see what happens ;- )

It could well turn out to be the success story of 2012. Or not! :o)

smiler

Email sent nice to see you and kim still around good luck with erx.

How are you Driver? ERX have extended their begging bowl again. Now we have until the 28th of this month to invest wisely/throw our money away. I had a phone call asking if I intended to subscribe; told them I don't know! The sensible side of my brain says don't touch it with a barge pole the other side says it would be a shame if ERX couldn't relist!

kim

Just put your dosh in RGM and wait, leave ERX to the punters LOL.

That sounds about right ;- ))

RGM looking good.

It is taking a long time for ERX to decided what to do but amazingly, they are still pottering on. There may yet be life (or lifesaving) here after all.

http://www.eirxtherapeutics.co.uk/auvation.html